<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928512</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457F2201</org_study_id>
    <secondary_id>2009-011000-34</secondary_id>
    <nct_id>NCT00928512</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)</brief_title>
  <official_title>A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in
      patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48
      with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457
      treatment in combination with MTX in RA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks</measure>
    <time_frame>16cweeks</time_frame>
    <description>A participant was considered to have achieved the incidence of response (ACR20 criteria) if he/she had at least a 20% improvement in both the tender and swollen 28-joint counts and had at least 20% improvement in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assesseddisability (Health Assessment Questionnaire [HAQ©] score)and acute phase rectant (C-reactive protein [hsCRP]/ESR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved an ACR50 or ACR70 Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>A participant was considered as improved according to the ACR50 or ACR70 criteria if he/she had at least a 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient self-assessed disability (Health Assessment Questionnaire [HAQ©] score) and Acute phase reactant (C-reactive protein [hsCRP]/ESR). Participants were defined as ACR50/70 responders at a given post-randomization visit if they satisfied the ACR50/70 criteria, respectively. Participants were considered ACR50/70 nonresponders if they failed the ACR50/70 criteria respectively. Participants who prematurely discontinued from study due to insufficient therapeutic effect were also considered nonresponders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved an ACR20, ACR50 or ACR70 Response up to Week 16</measure>
    <time_frame>at Weeks2, 4, 8, 12, 16</time_frame>
    <description>A participant was considered as improved according to the ACR20, ACR50 or ACR70 criteria if he/she had as least a 20%, 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assessed disability and acute phase rectant or Erythrocyte sedimentation rate (ESR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score 28 Using CRP (DAS28-CRP)</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient's 'global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission. The DAS28-CRP was derived from swollen joint count, tender joint count, hsCRP and patient's global assessment of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcome Short Form (36) Health Survey (SF-36® v2)</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health) which can be aggregated to derive a physical-component summary score and a mental-component score. Scores are normally determined with the use of norm-based methods which standardize scores based on an assessment of the general U.S. population free of chronic conditions. The scores range for each subscale from 0 to 10, and the composite score ranges from 0 to 100, with the higher scores indicative of better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much) based on their experience of fatigue during the past 2 weeThe scale score was computed by summing the item scores, after reversing those items that were worded in the negative direction. When there were missing item scores, the subscale score was computed by summing the non-missing item scores, multiplying by 13 (the total number of items in the scale) and dividing by the number of non-missing items. The latter rule applied only when at least half of the items (seven or more) were non-missing. FACIT-Fatigue subscale scores range from 0 to 52, where higher scores represent less fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The distribution of EULAR response criteria was according to DAS28-CRP at Week 16. EULAR response criteria are based on DAS28-CRP status in combination with DAS28-CRP improvements. The EULAR response criteria are as follows: Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement &gt;1.2 corresponds to 'good response'; Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement between 0.6 to 1.2, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement &gt;1.2 or from 0.6 to 1.2, or WeeK 16 DAS28-CRP &gt;5.1 with DAS28-CRP improvement &gt;1.2 correspond to 'moderate response; Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement &lt;0.6, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement &lt;0.6, or Week 16 DAS28-CRP &gt;5.1 with DAS28-CRP improvement between 0.6 to 1.2 or &lt;0.6 correspond to 'no response'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rheumatoid Factor (RF) Concentrations at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Only values that were above normal range (12 U/mL) were were included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-CCP (Cyclic Citrulinated Peptide) Antibodies Concentrations at Baseline and at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Only values that were above normal range (20 units) were included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACR Component: Adjusted Swollen 28-joint Count at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive result for swollen joint count. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. Whenever possible, the same evaluator performed these assessments at all visits. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., S) was less than 28, the number of swollen joints (e.g., s) was scaled up proportionately (i.e., 28*(s/S)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score 28 Using ESR (DAS28-ESR) at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient's 'global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission.The DAS28 was also derived using erythrocyte sedimentation rate (ESR) (referred to as DAS28-ESR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACR Component: Adjusted Tender 28-joint Count at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>The ACR tender joint count (28 joints) was done by scoring several different aspects of tenderness as assessed by pressure and joint manipulation on physical examination. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., T) was less than 28, the number of tender joints (e.g., t) was scaled up proportionately (i.e., 28*(t/T)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACR Component: Patient's Assessment of RA Pain at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>The patient's assessment of pain was performed at all visits using 100 mm visual analog scale (VAS) ranging from &quot;no pain&quot; to &quot;unbearable pain&quot; after the question &quot;Please indicate with a vertical mark ( | ) through the horizontal line the most pain you had from your rheumatoid arthritis over the last 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACR Component: Patient's Global Assessment of Disease Activity at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>The patient's global assessment of disease activity was performed at the visits on a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, &quot;Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACR Component: Physician's Global Assessment of Disease Activity at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>The physician's global assessment of disease activity was performed at the visits usingon a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, &quot;Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACR Component: Health Assessment Questionnaire (HAQ©) Score at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>HAQ© was used to assess physical ability and functional status of patients as well as quality of life at the visits in these 8 categories assessed by the Disability Index: dressing &amp; grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Patients report amount of difficulty they have in performing 2 or 3 specific activities. There are 4 possible responses (0, 1, 2, 3) for these questions which include types of assistance, if any; the participant uses for his/her usual activities: 0: without any difficulty- No assistance is needed; 1: with some difficulty - A special device is used by the patient in his/her usual activities; 2: with much difficulty - The patient usually needs help from another person. 3: Unable to do - the patient usually needs both a special device and help from another person. Scores of 0 - 1 are generally considered to represent mild to moderate difficulty, 1-2 moderate to severe disability, and 2 -3 severe to very severe disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACR Component: High Sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>Blood for this assessment was obtained at the visits in order to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.Since the results of this test may have unblinded study personnel, results from the central lab were provided for screening and baseline only. The hsCRP results from samples collected during the treatment period were revealed only after final database lock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACR Component: Erythrocyte Sedimentation Rate (ESR) at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>Blood for ESR, which is helpful to diagnose inflammatory diseases and to monitor disease activity and response to therapy, was obtained at the visits.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">237</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Secukinumab 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 25mg s.c. q4wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 75mg s.c. q4wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 150mg s. c. q4wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 300mg s.c. q4wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Secukinumab Placebo s.c. q4wk</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinmab</intervention_name>
    <description>Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.</description>
    <arm_group_label>Secukinumab 25mg</arm_group_label>
    <arm_group_label>Secukinumab 75mg</arm_group_label>
    <arm_group_label>Secukinumab 150mg</arm_group_label>
    <arm_group_label>Secukinumab 300mg</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.</description>
    <arm_group_label>Secukinumab Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of RA classified by ACR 1987 revised criteria. Patients with active RA should
             have been on MTX for at least 3 months and must currently be treated with a stable
             dose of MTX (&gt; or =7.5 mg/week - &lt; or = 25 mg/week) for at least 4 weeks

          -  At Baseline: Disease activity criteria defined by &gt; or = 6 out of 28 tender joints and
             &gt; or = 6 out of 28 swollen joints WITH either Screening value of hsCRP &gt; or = 10 mg/L
             OR ESR &gt; or = 28 mm/1st hr

        Exclusion Criteria:

          -  RA patients functional status class IV classified according to the ACR 1991 revised
             criteria

          -  Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or
             morphine)

          -  Any therapy by intra-articular injections (e.g. corticosteroid) required for treatment
             of acute RA flare within 4 weeks before randomization

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135-2920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <zip>72200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iizuka-city</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>658-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sagamihara-city</city>
        <state>Kanagawa</state>
        <zip>228-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350-1103</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-337</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129327</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>194104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tver</city>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>040 15</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piestany</city>
        <state>Slovak Republic</state>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <state>Taiwan ROC</state>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81346</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <results_first_submitted>February 12, 2015</results_first_submitted>
  <results_first_submitted_qc>July 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2015</results_first_posted>
  <disposition_first_submitted>May 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 6, 2012</disposition_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis, RA, ACR, inflammatory joints</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 16 patients discontinued prior to Week 16.At Week 20, all patients on secukinumab 25-150 mg who were responders continued on their randomized dose regimens. Non-responders in the 25 mg and 75 mg groups were up-titrated to 150 mg and non-responders in the 150 mg group were up-titrated to 300 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab 300mg</title>
          <description>Secukinumab 300mg s.c. q4wk</description>
        </group>
        <group group_id="P2">
          <title>Secukinumab 150mg</title>
          <description>Secukinumab 150mg s.c. q4wk</description>
        </group>
        <group group_id="P3">
          <title>Secukinumab 75mg</title>
          <description>Secukinumab 75mg s.c. q4wk</description>
        </group>
        <group group_id="P4">
          <title>Secukinumab 25mg</title>
          <description>Secukinumab 25mg s.c. q4wk</description>
        </group>
        <group group_id="P5">
          <title>Secukinumab Placebo</title>
          <description>Secukinumab Placebo s.c. q4wk</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Prior to Week 16</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Reassigned at Week 20 (Non-responders)</title>
              <participants_list>
                <participants group_id="P1" count="0">All patients in the 300 mg group at Week 20 remained at this dose in this group.</participants>
                <participants group_id="P2" count="23">Non-responders in the AIN457 150 mg group were reassigned treatment to the 300 mg group.</participants>
                <participants group_id="P3" count="23">Non-responders in the AIN457 75 mg group were reassigned treatment to the 150 mg group.</participants>
                <participants group_id="P4" count="27">Non-responders in the AIN457 25 mg group were reassigned treatment to the 150 mg group.</participants>
                <participants group_id="P5" count="45">All placebo patients (responders &amp; non-responders) were reassigned treatment to the 150 mg group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Reassigned at Week 20 (Responders)</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>New Groups After Reassignment</title>
              <participants_list>
                <participants group_id="P1" count="60">1 patient in this group continued at Week 16 but did not receive any study drug at Week 20.</participants>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="23">1 patient in this group continued at Week 16 but did not receive any study drug at Week 20.</participants>
                <participants group_id="P4" count="18">2 patients in this group continued at Week 16 but did not receive any study drug at Week 20</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Week 16</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered/Continued to Week 20 (All)</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The randomized set was defined as all subjects being randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab 300mg</title>
          <description>Secukinumab 300mg s.c. q4wk</description>
        </group>
        <group group_id="B2">
          <title>Secukinumab 150mg</title>
          <description>Secukinumab 150mg s.c. q4wk</description>
        </group>
        <group group_id="B3">
          <title>Secukinumab 75mg</title>
          <description>Secukinumab 75mg s.c. q4wk</description>
        </group>
        <group group_id="B4">
          <title>Secukinumab 25mg</title>
          <description>Secukinumab 25mg s.c. q4wk</description>
        </group>
        <group group_id="B5">
          <title>Secukinumab Placebo</title>
          <description>Secukinumab Placebo s.c. q4wk</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="54"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="237"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="10.61"/>
                    <measurement group_id="B2" value="57.8" spread="11.23"/>
                    <measurement group_id="B3" value="54.3" spread="9.84"/>
                    <measurement group_id="B4" value="53.3" spread="11.44"/>
                    <measurement group_id="B5" value="55.0" spread="10.46"/>
                    <measurement group_id="B6" value="54.9" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=18 - &lt; 41 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=41 - &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 - &lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographical Region</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>East Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-East Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Functional Status</title>
          <description>ACR classification criteria of functional status in rheumatoid arthritis: Class l: completely able to perform usual activities of daily living (self-care, vocational &amp; avocational); Class ll: able to perform usual self-care and vocational activities but limited in avocational activities; Class lll: able to perform usual self-care activities but limited in vocational and avocational activities; Class IV: limited ability to perform usual self-care, vocational and avocational activities.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class ll</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class lll</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.9" spread="23.91"/>
                    <measurement group_id="B2" value="72.1" spread="16.52"/>
                    <measurement group_id="B3" value="74.3" spread="15.70"/>
                    <measurement group_id="B4" value="71.3" spread="14.16"/>
                    <measurement group_id="B5" value="75.9" spread="15.61"/>
                    <measurement group_id="B6" value="74.3" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight Group</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;90 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=90 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.3" spread="10.03"/>
                    <measurement group_id="B2" value="161.9" spread="10.84"/>
                    <measurement group_id="B3" value="165.4" spread="9.52"/>
                    <measurement group_id="B4" value="163.2" spread="7.07"/>
                    <measurement group_id="B5" value="166.1" spread="7.62"/>
                    <measurement group_id="B6" value="164.0" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (body mass index)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.48" spread="8.383"/>
                    <measurement group_id="B2" value="27.32" spread="4.673"/>
                    <measurement group_id="B3" value="27.03" spread="4.936"/>
                    <measurement group_id="B4" value="26.69" spread="4.768"/>
                    <measurement group_id="B5" value="24.47" spread="5.229"/>
                    <measurement group_id="B6" value="27.52" spread="5.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks</title>
        <description>A participant was considered to have achieved the incidence of response (ACR20 criteria) if he/she had at least a 20% improvement in both the tender and swollen 28-joint counts and had at least 20% improvement in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assesseddisability (Health Assessment Questionnaire [HAQ©] score)and acute phase rectant (C-reactive protein [hsCRP]/ESR).</description>
        <time_frame>16cweeks</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks</title>
          <description>A participant was considered to have achieved the incidence of response (ACR20 criteria) if he/she had at least a 20% improvement in both the tender and swollen 28-joint counts and had at least 20% improvement in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assesseddisability (Health Assessment Questionnaire [HAQ©] score)and acute phase rectant (C-reactive protein [hsCRP]/ESR).</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved an ACR50 or ACR70 Response at Week 16</title>
        <description>A participant was considered as improved according to the ACR50 or ACR70 criteria if he/she had at least a 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient self-assessed disability (Health Assessment Questionnaire [HAQ©] score) and Acute phase reactant (C-reactive protein [hsCRP]/ESR). Participants were defined as ACR50/70 responders at a given post-randomization visit if they satisfied the ACR50/70 criteria, respectively. Participants were considered ACR50/70 nonresponders if they failed the ACR50/70 criteria respectively. Participants who prematurely discontinued from study due to insufficient therapeutic effect were also considered nonresponders.</description>
        <time_frame>Week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved an ACR50 or ACR70 Response at Week 16</title>
          <description>A participant was considered as improved according to the ACR50 or ACR70 criteria if he/she had at least a 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient self-assessed disability (Health Assessment Questionnaire [HAQ©] score) and Acute phase reactant (C-reactive protein [hsCRP]/ESR). Participants were defined as ACR50/70 responders at a given post-randomization visit if they satisfied the ACR50/70 criteria, respectively. Participants were considered ACR50/70 nonresponders if they failed the ACR50/70 criteria respectively. Participants who prematurely discontinued from study due to insufficient therapeutic effect were also considered nonresponders.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved an ACR20, ACR50 or ACR70 Response up to Week 16</title>
        <description>A participant was considered as improved according to the ACR20, ACR50 or ACR70 criteria if he/she had as least a 20%, 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assessed disability and acute phase rectant or Erythrocyte sedimentation rate (ESR).</description>
        <time_frame>at Weeks2, 4, 8, 12, 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved an ACR20, ACR50 or ACR70 Response up to Week 16</title>
          <description>A participant was considered as improved according to the ACR20, ACR50 or ACR70 criteria if he/she had as least a 20%, 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assessed disability and acute phase rectant or Erythrocyte sedimentation rate (ESR).</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: ACR20 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: ACR50 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: ACR70 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: ACR20 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: ACR50 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: ACR70 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: ACR20 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: ACR50 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: ACR70 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: ACR20 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: ACR50 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: ACR70 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: ACR20 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: ACR50 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: ACR70 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score 28 Using CRP (DAS28-CRP)</title>
        <description>The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient’s ‘global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission. The DAS28-CRP was derived from swollen joint count, tender joint count, hsCRP and patient’s global assessment of disease activity.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score 28 Using CRP (DAS28-CRP)</title>
          <description>The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient’s ‘global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission. The DAS28-CRP was derived from swollen joint count, tender joint count, hsCRP and patient’s global assessment of disease activity.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="0.186"/>
                    <measurement group_id="O2" value="-1.35" spread="0.181"/>
                    <measurement group_id="O3" value="-1.46" spread="0.170"/>
                    <measurement group_id="O4" value="-1.13" spread="0.165"/>
                    <measurement group_id="O5" value="-0.96" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcome Short Form (36) Health Survey (SF-36® v2)</title>
        <description>The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health) which can be aggregated to derive a physical-component summary score and a mental-component score. Scores are normally determined with the use of norm-based methods which standardize scores based on an assessment of the general U.S. population free of chronic conditions. The scores range for each subscale from 0 to 10, and the composite score ranges from 0 to 100, with the higher scores indicative of better health.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcome Short Form (36) Health Survey (SF-36® v2)</title>
          <description>The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health) which can be aggregated to derive a physical-component summary score and a mental-component score. Scores are normally determined with the use of norm-based methods which standardize scores based on an assessment of the general U.S. population free of chronic conditions. The scores range for each subscale from 0 to 10, and the composite score ranges from 0 to 100, with the higher scores indicative of better health.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>scores on a scale-change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 physical component score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="5.574" lower_limit="-2.66" upper_limit="3.60"/>
                    <measurement group_id="O2" value="4.51" spread="6.800" lower_limit="-2.07" upper_limit="3.58"/>
                    <measurement group_id="O3" value="3.48" spread="5.961" lower_limit="-2.05" upper_limit="3.32"/>
                    <measurement group_id="O4" value="2.15" spread="7.176" lower_limit="-3.40" upper_limit="2.33"/>
                    <measurement group_id="O5" value="2.47" spread="7.481" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 mental component score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="11.421" lower_limit="-5.95" upper_limit="3.82"/>
                    <measurement group_id="O2" value="3.59" spread="9.631" lower_limit="-3.08" upper_limit="4.41"/>
                    <measurement group_id="O3" value="2.58" spread="11.479" lower_limit="-4.72" upper_limit="3.05"/>
                    <measurement group_id="O4" value="1.06" spread="9.299" lower_limit="-2.07" upper_limit="5.03"/>
                    <measurement group_id="O5" value="1.10" spread="10.231" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 16</title>
        <description>The Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much) based on their experience of fatigue during the past 2 weeThe scale score was computed by summing the item scores, after reversing those items that were worded in the negative direction. When there were missing item scores, the subscale score was computed by summing the non-missing item scores, multiplying by 13 (the total number of items in the scale) and dividing by the number of non-missing items. The latter rule applied only when at least half of the items (seven or more) were non-missing. FACIT-Fatigue subscale scores range from 0 to 52, where higher scores represent less fatigue.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 16</title>
          <description>The Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much) based on their experience of fatigue during the past 2 weeThe scale score was computed by summing the item scores, after reversing those items that were worded in the negative direction. When there were missing item scores, the subscale score was computed by summing the non-missing item scores, multiplying by 13 (the total number of items in the scale) and dividing by the number of non-missing items. The latter rule applied only when at least half of the items (seven or more) were non-missing. FACIT-Fatigue subscale scores range from 0 to 52, where higher scores represent less fatigue.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>scores on a scale-change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="7.181" lower_limit="-1.25" upper_limit="6.00"/>
                    <measurement group_id="O2" value="5.18" spread="8.470" lower_limit="-2.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="3.89" spread="8.368" lower_limit="-2.00" upper_limit="5.00"/>
                    <measurement group_id="O4" value="1.95" spread="8.232" lower_limit="3.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="1.64" spread="8.464" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 16</title>
        <description>The distribution of EULAR response criteria was according to DAS28-CRP at Week 16. EULAR response criteria are based on DAS28-CRP status in combination with DAS28-CRP improvements. The EULAR response criteria are as follows: Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement &gt;1.2 corresponds to 'good response'; Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement between 0.6 to 1.2, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement &gt;1.2 or from 0.6 to 1.2, or WeeK 16 DAS28-CRP &gt;5.1 with DAS28-CRP improvement &gt;1.2 correspond to 'moderate response; Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement &lt;0.6, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement &lt;0.6, or Week 16 DAS28-CRP &gt;5.1 with DAS28-CRP improvement between 0.6 to 1.2 or &lt;0.6 correspond to 'no response'.</description>
        <time_frame>Week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 16</title>
          <description>The distribution of EULAR response criteria was according to DAS28-CRP at Week 16. EULAR response criteria are based on DAS28-CRP status in combination with DAS28-CRP improvements. The EULAR response criteria are as follows: Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement &gt;1.2 corresponds to 'good response'; Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement between 0.6 to 1.2, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement &gt;1.2 or from 0.6 to 1.2, or WeeK 16 DAS28-CRP &gt;5.1 with DAS28-CRP improvement &gt;1.2 correspond to 'moderate response; Week 16 DAS28-CRP &lt;3.2 with DAS28-CRP improvement &lt;0.6, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement &lt;0.6, or Week 16 DAS28-CRP &gt;5.1 with DAS28-CRP improvement between 0.6 to 1.2 or &lt;0.6 correspond to 'no response'.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="18.9"/>
                    <measurement group_id="O5" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="41.9"/>
                    <measurement group_id="O3" value="46.9"/>
                    <measurement group_id="O4" value="30.2"/>
                    <measurement group_id="O5" value="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="39.5"/>
                    <measurement group_id="O3" value="30.6"/>
                    <measurement group_id="O4" value="50.9"/>
                    <measurement group_id="O5" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rheumatoid Factor (RF) Concentrations at Week 16</title>
        <description>Only values that were above normal range (12 U/mL) were were included.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rheumatoid Factor (RF) Concentrations at Week 16</title>
          <description>Only values that were above normal range (12 U/mL) were were included.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.66" spread="210.235"/>
                    <measurement group_id="O2" value="-32.11" spread="196.574"/>
                    <measurement group_id="O3" value="-77.62" spread="341.985"/>
                    <measurement group_id="O4" value="66.44" spread="379.723"/>
                    <measurement group_id="O5" value="85.63" spread="499.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-CCP (Cyclic Citrulinated Peptide) Antibodies Concentrations at Baseline and at Week 16</title>
        <description>Only values that were above normal range (20 units) were included.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-CCP (Cyclic Citrulinated Peptide) Antibodies Concentrations at Baseline and at Week 16</title>
          <description>Only values that were above normal range (20 units) were included.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Concentrations at baseline (n: 33, 32, 43, 46, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1444.67" spread="1450.438"/>
                    <measurement group_id="O2" value="1098.81" spread="1238.627"/>
                    <measurement group_id="O3" value="1178.88" spread="1390.458"/>
                    <measurement group_id="O4" value="1342.50" spread="1544.205"/>
                    <measurement group_id="O5" value="1406.79" spread="1496.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentrations at Week 16 (n: 30, 30, 41, 42, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1478.53" spread="1767.070"/>
                    <measurement group_id="O2" value="1330.63" spread="1355.193"/>
                    <measurement group_id="O3" value="1155.27" spread="1550.003"/>
                    <measurement group_id="O4" value="1443.07" spread="1640.771"/>
                    <measurement group_id="O5" value="1556.06" spread="1596.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACR Component: Adjusted Swollen 28-joint Count at Week 16</title>
        <description>Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive result for swollen joint count. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. Whenever possible, the same evaluator performed these assessments at all visits. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., S) was less than 28, the number of swollen joints (e.g., s) was scaled up proportionately (i.e., 28*(s/S)).</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACR Component: Adjusted Swollen 28-joint Count at Week 16</title>
          <description>Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive result for swollen joint count. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. Whenever possible, the same evaluator performed these assessments at all visits. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., S) was less than 28, the number of swollen joints (e.g., s) was scaled up proportionately (i.e., 28*(s/S)).</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>swollen joints</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="0.75"/>
                    <measurement group_id="O2" value="-5.2" spread="0.73"/>
                    <measurement group_id="O3" value="-6.0" spread="0.68"/>
                    <measurement group_id="O4" value="-4.4" spread="0.66"/>
                    <measurement group_id="O5" value="-4.6" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score 28 Using ESR (DAS28-ESR) at Week 16</title>
        <description>The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient’s ‘global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission.The DAS28 was also derived using erythrocyte sedimentation rate (ESR) (referred to as DAS28-ESR).</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score 28 Using ESR (DAS28-ESR) at Week 16</title>
          <description>The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient’s ‘global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission.The DAS28 was also derived using erythrocyte sedimentation rate (ESR) (referred to as DAS28-ESR).</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="0.196"/>
                    <measurement group_id="O2" value="-1.55" spread="0.191"/>
                    <measurement group_id="O3" value="-1.65" spread="0.179"/>
                    <measurement group_id="O4" value="-1.28" spread="0.174"/>
                    <measurement group_id="O5" value="-1.14" spread="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACR Component: Adjusted Tender 28-joint Count at Week 16</title>
        <description>The ACR tender joint count (28 joints) was done by scoring several different aspects of tenderness as assessed by pressure and joint manipulation on physical examination. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., T) was less than 28, the number of tender joints (e.g., t) was scaled up proportionately (i.e., 28*(t/T)).</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACR Component: Adjusted Tender 28-joint Count at Week 16</title>
          <description>The ACR tender joint count (28 joints) was done by scoring several different aspects of tenderness as assessed by pressure and joint manipulation on physical examination. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., T) was less than 28, the number of tender joints (e.g., t) was scaled up proportionately (i.e., 28*(t/T)).</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>tender joints</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="0.94"/>
                    <measurement group_id="O2" value="-6.5" spread="0.91"/>
                    <measurement group_id="O3" value="-6.3" spread="0.86"/>
                    <measurement group_id="O4" value="-5.6" spread="0.83"/>
                    <measurement group_id="O5" value="-5.0" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACR Component: Patient's Assessment of RA Pain at Week 16</title>
        <description>The patient's assessment of pain was performed at all visits using 100 mm visual analog scale (VAS) ranging from &quot;no pain&quot; to &quot;unbearable pain&quot; after the question &quot;Please indicate with a vertical mark ( | ) through the horizontal line the most pain you had from your rheumatoid arthritis over the last 24 hours.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACR Component: Patient's Assessment of RA Pain at Week 16</title>
          <description>The patient's assessment of pain was performed at all visits using 100 mm visual analog scale (VAS) ranging from &quot;no pain&quot; to &quot;unbearable pain&quot; after the question &quot;Please indicate with a vertical mark ( | ) through the horizontal line the most pain you had from your rheumatoid arthritis over the last 24 hours.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>VAS in mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="3.25"/>
                    <measurement group_id="O2" value="-9.1" spread="3.16"/>
                    <measurement group_id="O3" value="-11.6" spread="2.97"/>
                    <measurement group_id="O4" value="-9.5" spread="2.88"/>
                    <measurement group_id="O5" value="-9.1" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACR Component: Patient's Global Assessment of Disease Activity at Week 16</title>
        <description>The patient’s global assessment of disease activity was performed at the visits on a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, &quot;Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing&quot;.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACR Component: Patient's Global Assessment of Disease Activity at Week 16</title>
          <description>The patient’s global assessment of disease activity was performed at the visits on a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, &quot;Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing&quot;.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>VAS in mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="3.27"/>
                    <measurement group_id="O2" value="-10.5" spread="3.19"/>
                    <measurement group_id="O3" value="-18.4" spread="2.99"/>
                    <measurement group_id="O4" value="-10.6" spread="2.90"/>
                    <measurement group_id="O5" value="-9.9" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACR Component: Physician’s Global Assessment of Disease Activity at Week 16</title>
        <description>The physician’s global assessment of disease activity was performed at the visits usingon a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, &quot;Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing&quot;.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACR Component: Physician’s Global Assessment of Disease Activity at Week 16</title>
          <description>The physician’s global assessment of disease activity was performed at the visits usingon a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, &quot;Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing&quot;.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>VAS in mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.8" spread="2.99"/>
                    <measurement group_id="O2" value="-26.7" spread="2.91"/>
                    <measurement group_id="O3" value="-25.4" spread="2.73"/>
                    <measurement group_id="O4" value="-18.1" spread="2.65"/>
                    <measurement group_id="O5" value="-15.2" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACR Component: Health Assessment Questionnaire (HAQ©) Score at Week 16</title>
        <description>HAQ© was used to assess physical ability and functional status of patients as well as quality of life at the visits in these 8 categories assessed by the Disability Index: dressing &amp; grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Patients report amount of difficulty they have in performing 2 or 3 specific activities. There are 4 possible responses (0, 1, 2, 3) for these questions which include types of assistance, if any; the participant uses for his/her usual activities: 0: without any difficulty- No assistance is needed; 1: with some difficulty - A special device is used by the patient in his/her usual activities; 2: with much difficulty - The patient usually needs help from another person. 3: Unable to do - the patient usually needs both a special device and help from another person. Scores of 0 - 1 are generally considered to represent mild to moderate difficulty, 1-2 moderate to severe disability, and 2 -3 severe to very severe disability.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACR Component: Health Assessment Questionnaire (HAQ©) Score at Week 16</title>
          <description>HAQ© was used to assess physical ability and functional status of patients as well as quality of life at the visits in these 8 categories assessed by the Disability Index: dressing &amp; grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Patients report amount of difficulty they have in performing 2 or 3 specific activities. There are 4 possible responses (0, 1, 2, 3) for these questions which include types of assistance, if any; the participant uses for his/her usual activities: 0: without any difficulty- No assistance is needed; 1: with some difficulty - A special device is used by the patient in his/her usual activities; 2: with much difficulty - The patient usually needs help from another person. 3: Unable to do - the patient usually needs both a special device and help from another person. Scores of 0 - 1 are generally considered to represent mild to moderate difficulty, 1-2 moderate to severe disability, and 2 -3 severe to very severe disability.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.297" spread="0.0698"/>
                    <measurement group_id="O2" value="-0.256" spread="0.0688"/>
                    <measurement group_id="O3" value="-0.233" spread="0.0639"/>
                    <measurement group_id="O4" value="-0.202" spread="0.0627"/>
                    <measurement group_id="O5" value="-0.116" spread="0.0652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACR Component: High Sensitivity C-reactive Protein (hsCRP)</title>
        <description>Blood for this assessment was obtained at the visits in order to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.Since the results of this test may have unblinded study personnel, results from the central lab were provided for screening and baseline only. The hsCRP results from samples collected during the treatment period were revealed only after final database lock.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACR Component: High Sensitivity C-reactive Protein (hsCRP)</title>
          <description>Blood for this assessment was obtained at the visits in order to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.Since the results of this test may have unblinded study personnel, results from the central lab were provided for screening and baseline only. The hsCRP results from samples collected during the treatment period were revealed only after final database lock.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>mg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.54" spread="2.237"/>
                    <measurement group_id="O2" value="-7.76" spread="2.175"/>
                    <measurement group_id="O3" value="-9.09" spread="2.042"/>
                    <measurement group_id="O4" value="-4.08" spread="1.984"/>
                    <measurement group_id="O5" value="0.30" spread="2.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACR Component: Erythrocyte Sedimentation Rate (ESR) at Week 16</title>
        <description>Blood for ESR, which is helpful to diagnose inflammatory diseases and to monitor disease activity and response to therapy, was obtained at the visits.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300mg</title>
            <description>Secukinumab 300mg s.c. q4wk</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150mg</title>
            <description>Secukinumab 150mg s.c. q4wk</description>
          </group>
          <group group_id="O3">
            <title>Secukinumab 75mg</title>
            <description>Secukinumab 75mg s.c. q4wk</description>
          </group>
          <group group_id="O4">
            <title>Secukinumab 25mg</title>
            <description>Secukinumab 25mg s.c. q4wk</description>
          </group>
          <group group_id="O5">
            <title>Secukinumab Placebo</title>
            <description>Secukinumab Placebo s.c. q4wk</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACR Component: Erythrocyte Sedimentation Rate (ESR) at Week 16</title>
          <description>Blood for ESR, which is helpful to diagnose inflammatory diseases and to monitor disease activity and response to therapy, was obtained at the visits.</description>
          <population>Full analysis set (FAS) all subjects to whom study drug was assigned. Following the intent-to-treat principle, subjects were analyzed according to the treatment they were assigned to at randomization. FAS did not include subjects who have missing values for all post-baseline (visit &gt;=3) assessments on all of the specified efficacy variables.</population>
          <units>mm/hr</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.51" spread="2.630"/>
                    <measurement group_id="O2" value="-15.06" spread="2.564"/>
                    <measurement group_id="O3" value="-15.43" spread="2.426"/>
                    <measurement group_id="O4" value="-9.86" spread="2.331"/>
                    <measurement group_id="O5" value="-6.12" spread="2.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AIN457 25mg</title>
          <description>Up to Week 20 - AIN457 25mg</description>
        </group>
        <group group_id="E2">
          <title>AIN457 75mg</title>
          <description>Up to Week 20 - AIN457 75mg</description>
        </group>
        <group group_id="E3">
          <title>AIN457 150mg</title>
          <description>Up to Week 20 - AIN457 150mg</description>
        </group>
        <group group_id="E4">
          <title>AIN457 300mg</title>
          <description>Up to Week 20 - AIN457 300mg</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Up to Week 20 - Placebo</description>
        </group>
        <group group_id="E6">
          <title>AIN457 25mg (Wk 20 to End of Study)</title>
          <description>From week 20 through end of study - AIN457 25mg</description>
        </group>
        <group group_id="E7">
          <title>AIN457 75mg (Wk 20 to End of Study)</title>
          <description>From week 20 through end of study - AIN457 75mg</description>
        </group>
        <group group_id="E8">
          <title>AIN457 150mg (Wk 20 to End of Study)</title>
          <description>From week 20 through end of study - AIN457 150mg</description>
        </group>
        <group group_id="E9">
          <title>AIN457 300mg (Wk 20 to End of Study)</title>
          <description>From week 20 through end of study - AIN457 300mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femoral hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rheumatoid vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="52" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="27" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Monocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyshidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

